About Us
Vision and Strategy
Management
Board
Advisors
History and Milestones
Group Structure
Technology
Overall Concept
Technical Implementation
Applications and Benefits
Compounds
EV-077 for Proteinuric Kidney Disease
EV-077 for Cardiovascular Disease
EV-086 for Invasive Fungal Infections
EV-086 for Topical Fungal Infections
EV-075 for Influenza
EV-075 for Haemorrhagic Fevers (in particular Ebola)
Other Compounds
Partnerships
Existing Partners
Partnering Approach
Newsroom
Investors
Chart
Stock and Key Figures
Financials
Finance History
Shareholder information
Contact
Stay Informed
Join Us
Job Opportunities
Work Environment
Diversity and Culture
Links
Contact Us
Contact Details
Locations and Directions
Join Mailing List
Financials
Financial reports Evolva SA
Evolva 2006-2008
First half 2009 English
Financial reports Arpida Ltd
Annual report 2005 English
German summary 2005
First half 2005 German
First half 2005 English
First half 2005 French
Annual report 2006 English
German summary 2006
First half 2006 German
First half 2006 English
Annual report 2007 English
German summary 2007
First half 2007 English
First half 2007 German
First half 2007 French
Annual report 2008 English
First half 2009 English
First half 2008 English
First half 2008 German
First half 2008 French
First half 2009 German
First half 2009 French
German summary 2008
Tools
Contact Information
Legal Statement
|
Login
